STOCK TITAN

Aptevo Therapeutics Inc - APVO STOCK NEWS

Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.

Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company based in Seattle, Washington, renowned for pioneering oncology and hematology therapeutics. The company leverages its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to develop novel immunotherapeutic candidates aimed at enhancing cancer treatment outcomes.

Aptevo's robust pipeline includes APVO436, a clinical candidate targeting acute myeloid leukemia (AML), as well as preclinical candidates ALG.APV-527 and APVO603. These candidates utilize the company's versatile technology platforms to generate bispecific and multi-specific antibody candidates that harness the human immune system to target cancer cells.

Recently, Aptevo announced a reverse stock split aimed at regaining compliance with NASDAQ's minimum bid price requirement. The split is part of a strategic plan approved by the shareholders and aims to reduce the number of outstanding shares, thereby increasing the share price.

Among its promising projects, APVO436 has shown significant clinical benefits in combination with venetoclax and azacitidine for frontline AML treatment. The company is preparing to initiate a Phase 1b/2 dose optimization study, further exploring its efficacy. Additionally, ALG.APV-527 is in a Phase 1 trial for multiple solid tumor types, showing early signs of clinical activity and biological effectiveness.

Aptevo's culture of innovation and collaboration has attracted leading minds from pioneering biotech firms, fostering an environment conducive to groundbreaking research and development. The company's latest news highlights ongoing initiatives, such as presenting new data at major conferences and securing strategic partnerships to advance its clinical programs.

Financially, Aptevo remains focused on clinical development and operational efficiency. In recent quarters, the company has reported decreases in research and development expenses due to the transition between phases of its clinical studies. General and administrative expenses have also seen reductions, primarily attributed to lower employee and consulting costs.

Looking ahead, Aptevo continues to advance its pipeline with the aim of transforming cancer treatment paradigms. This commitment is underscored by their participation in major industry conferences and ongoing collaborations with leading CROs and biopharmaceutical firms.

Rhea-AI Summary

Aptevo Therapeutics Inc. reported positive outcomes from its clinical trials, with a breast cancer patient showing stable disease for over eleven months on a higher dose level. The company is set to start a dose optimization trial for APVO436 in 2Q 2024. Financially, Aptevo's cash position was $10.3 million as of March 31, 2024, with reduced research and development expenses and general administrative expenses. However, the company reported a net loss of $6.8 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.64%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) closes a $4.6 million public offering, selling 3,400,000 shares of common stock and warrants to purchase 6,800,000 shares at $1.35 per share. The company plans to use the proceeds for clinical development, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) announces a public offering of 3.4 million shares of common stock and warrants to purchase 6.8 million shares at $1.35 per share. Each share comes with two Common Warrants, with an exercise price of $1.35 per share, expiring in five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.08%
Tags
Rhea-AI Summary
Aptevo Therapeutics Inc. (APVO) announces positive advancements in clinical and preclinical programs, including a breast cancer patient transitioning to a higher dose level in the ALG.APV-527 trial, APVO436 Phase 1b/2 trial initiation expected in 1H 2024, and engagement of Prometrika as a partner for dose optimization trial. APVO711 shows promise in inducing tumor killing properties in preclinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.38%
Tags
none
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) is participating in The Springtime Event, a Bio-Europe conference in Barcelona, Spain. The event aims to foster relationships within the biotechnology and biopharmaceutical industries, with key representatives from Aptevo attending.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
none
-
Rhea-AI Summary
Alligator Bioscience and Aptevo Therapeutics announce positive interim data for ALG.APV-527 in Phase 1 trial for solid tumors expressing tumor antigen 5T4. The trial shows favorable drug exposure, biological activity, and signs of clinical activity in heavily pretreated patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
Rhea-AI Summary
Aptevo Therapeutics Inc. announces 1H24 plan for the development of lead candidate APVO436 for frontline acute myeloid leukemia. Interim results expected late 2H24. Phase 1 trial for APV-527 for multiple solid tumors continues enrollment, with interim results expected 1H24. Financial results for 2023 and business update provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced a 1-for-44 reverse stock split to regain Nasdaq compliance, reducing outstanding shares from 23.5 million to approximately 0.53 million. The split aims to maintain a minimum bid price of $1.00 per share and will not change the trading symbol 'APVO'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.41%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ: APVO) reported financial results and provided a business update, including progress in the ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors, planning for APVO436 Phase 2 Trial Initiation, and extended cash runway with $7 million in funding and potential for additional $9.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.7%
Tags
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) will present at the Bio-Europe conference in Munich, Germany from November 6-8, 2023. The presentation will focus on the company's pipeline of clinical and pre-clinical bispecific drug candidates for treating solid and hematologic malignancies. Michelle Nelson, Ph.D., Director of Immunobiology, will be the presenter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
conferences

FAQ

What is the current stock price of Aptevo Therapeutics (APVO)?

The current stock price of Aptevo Therapeutics (APVO) is $4.71 as of December 23, 2024.

What is the market cap of Aptevo Therapeutics (APVO)?

The market cap of Aptevo Therapeutics (APVO) is approximately 2.2M.

What is Aptevo Therapeutics Inc.?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for cancer treatment.

What technologies does Aptevo Therapeutics use?

Aptevo Therapeutics uses proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to develop its immunotherapeutic candidates.

What are the key clinical candidates of Aptevo Therapeutics?

The key clinical candidates include APVO436 for acute myeloid leukemia (AML), ALG.APV-527 for multiple solid tumors, and APVO603.

Where is Aptevo Therapeutics headquartered?

Aptevo Therapeutics is headquartered in Seattle, Washington.

What recent financial measures has Aptevo taken?

Recently, Aptevo announced a reverse stock split to regain NASDAQ compliance and reduce the number of outstanding shares.

What is ADAPTIR™ technology?

ADAPTIR™ technology is a versatile platform designed to create bispecific and multi-specific antibodies that enhance the immune system's ability to target cancer cells.

What recent achievements has APVO436 made?

APVO436 has shown a 91% clinical benefit rate in combination with venetoclax and azacitidine for treating AML and is moving into a Phase 1b/2 dose optimization study.

What is ALG.APV-527?

ALG.APV-527 is a clinical candidate being evaluated for multiple solid tumors, currently in a Phase 1 dose escalation trial.

How is Aptevo's financial health regarding R&D expenses?

Aptevo has reported a decrease in research and development expenses, primarily due to transitioning between clinical study phases.

What is Aptevo's approach to innovation?

Aptevo fosters an environment of innovation and collaboration, attracting leading experts from pioneering biotech firms and focusing on groundbreaking research in cancer treatment.

Aptevo Therapeutics Inc

Nasdaq:APVO

APVO Rankings

APVO Stock Data

2.24M
1.46M
0.03%
11.36%
3.97%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SEATTLE